Amnestic Mild
Cognitive Impairment

Our Focus

Amnestic Mild Cognitive Impairment (aMCI) is another increasingly prevalent disease condition that affects millions of elderly patients. Despite not being generally acknowledged, aMCI currently affects up to 18% of people aged 60 and over. From those suffering from aMCI, 15% could develop dementia within one year and up to 33% of may develop Alzheimer’s disease within five years.

Currently, there is only one approved therapeutic drug available on the market, which has been mired in controversy due to the results obtained from its clinical studies presented to FDA. ECP Pharma, instead of targeting amyloid plaques which is a key biomarker in patients with Alzheimer’s Disease, will focus on treating the neurological changes in the brain occurring in patients with aMCI prior to the on-set of dementia and Alzheimer’s Disease.

What is aMCI?

aMCI is an early stage of memory loss or other cognitive ability that causes individuals no longer being able to independently perform most activities of daily living.

It is important to note that aMCI can develop for multiple reasons which are not clearly understood. For some, aMCI can revert to normal cognition or remain stable. For others, aMCI can progress to worsening states such as dementia and Alzheimer’s Disease. What is certain, is that developing aMCI puts a patient at a much greater risk for developing neurodegenerative diseases.

Current Treatments

There is only one approved treatment that may delay clinical decline of patients suffering from Alzheimer’s disease, and several other treatments that alleviate cognitive and non-cognitive symptoms of patients suffering from Alzheimer’s disease. All of these treatments have numerous side effects and target either mild to severe dementia or Alzheimer’s disease. There are currently no treatments targeting aMCI or the prevention or retardation of aMCI from progressing to dementia / Alzheimer’s disease.

ECP Pharma's Research & Treatment Method

ECP Pharma’s research and drug development program is currently evaluating a variety of active pharmaceutical ingredients in line with a two-dose therapy which provides the greatest potential to treat aMCI by reversing the cognitive decline.